Abogen Biosciences' mRNA Therapeutic Cancer Vaccine ABO2102 Receives IND Approval in China and the U.S. for KRAS-Mutant Solid Tumors

The official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration recently announced that Abogen's application for the new drug ABO2102 has received clinical trial authorization.ABO2102 Monotherapy or in Combination with Sintilimab TreatmentKRASLocally Advanced or Metastatic Solid Tumors with Mutations. Public information shows that ABO2102 is a product developed by Abogen.Covering multiple types simultaneouslyKRASNovel mRNA tumor vaccine with mutations, suitable for carriersKRASPatients with solid tumors harboring any of the five common mutations. The product has received clinical trial approval from the U.S. FDA in May this year.

KRASMutation is one of the most common oncogenic mutations in solid tumors and is often associated with malignant tumors. Despite recent breakthroughs in KRAS G12C small-molecule inhibitors, some limitations still need to be addressed, such asInevitable drug resistance, survival benefits for some patients still need improvement, etc.。

According toIntroduction,ABO2102 Therapeutic Cancer Vaccine Demonstrates Promising Antitumor Activity in Preclinical Studies and Achieves Broad Coverage of HLA (Human Leukocyte Antigen) Subtypes. The vaccine features a multi-target antigen design:At the same time, five common types were encodedKRASThe mRNA molecules of mutant antigens are translated into antigens within the cell and then presented via MHC-I/II molecules, activating a dual immune response of CD8⁺ cytotoxic T cells and CD4⁺ helper T cells to achieveKRASPrecise Recognition and Attack of Mutant Antigens.Therefore, this vaccine product can cover a wider range ofKRASMutation type.

Preclinical data show that the T cells activated by this vaccine can accurately recognizeKRASNew antigens on the surface of mutated cells effectively kill tumor cells.This endogenous immune response not only avoids the common off-target toxicity of targeted drugs but also continuously suppresses tumor recurrence through immune memory mechanisms.Preclinical studies also showed that ABO2102 combined with PD-1 inhibitor has a synergistic effect, further enhancing anti-tumor efficacy.

References:

[1]Dual FDA and NMPA Approval: Abogen Biosciences' mRNA Therapeutic Cancer Vaccine Approved for Clinical Trials. From https://mp.weixin.qq.com/s/BEmAg9MorCdhGXX8E4-n1Q